 STOCKHOLM, Nov. 9, 2020 PRNewswire -- On November 8, 2020, Calliditas announced positive topline results from Part A of the global Phase 3 clinical trial NefIgArd, which investigated the effect of Nefecon versus placebo in patients with primary IgA nephropathy IgAN. Calliditas will... 